resected NSCLC(stage II - IIIB)
Conditions
Interventions
CBDCA(AUC 5, day1) plus nab-PTX(100mg/m2,day1,8,15) 4 cycles
Sponsors
Division of Respiratory Medicine, Department of Internal Medicine,Kobe University Graduate School of Medicine
Division of Respiratory surgery, Kobe University Graduate School of Medicine
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: (1)The patient histologically proven as non-small cell lung cancer (2)The patient with p-staged II - IIIB that received segmentectomy, lobectomy, or bi-lobectomy (3) Performance Status is 0 - 1 (ECOG). (4) 20 years of age or older (5) The patient who does not receive any chemotherapy, radiotherapy, or immunotherapy prior to resection (6) The patient who preserves the main organ ( the bone marrow, liver, kidney and so on ) (7) The patient who can receive chemotherapy within 4 - 8 weeks after resection (8) The patient who gives written informed consent
Exclusion criteria
Exclusion criteria: (1)The patient with infection (2)The patient with fever (equal to or more than 38 C) (3)The patient with heavy complication (4)The patient with active double-cancer (5)The patient with uncontrolled pleural effuson (6)The patient with a motor-palsy or figure of peripheral-nerve-disease (7)The patient with drug hypersensitivity (8)The patient with common use of NSAIDs (9)The expectant mother, the woman who has a lactating-woman and the possibility of the pregnancy (10)The patient judged as unsuitable by the doctor
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| safety | — |
Secondary
| Measure | Time frame |
|---|---|
| 1.Chemotherapy compliance in the four cycles 2.2-years disease free survival | — |
Countries
Japan
Contacts
Public ContactMotoko Tachihara
Kobe University Graduate School of Medicine Division of Respiratory Medicine, Department of Internal Medicine
Outcome results
None listed